Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies-Reference-Cited by-同舟云学术

Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies

Published:2020-10-27 Issue:1 Volume:106 Page:105-113
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur. J. Haematol.

Author:

Zucenka Andrius¹^ORCID,Pileckyte Regina¹²^ORCID,Trociukas Igoris²,Peceliunas Valdas¹²,Vaitekenaite Vilmante¹^ORCID,Maneikis Kazimieras²,Davainis Linas²,Zvirblis Tadas²,Stoskus Mindaugas²,Gineikiene Egle²,Norvilas Rimvydas²,Dirse Vaidas²,Surauciute Agne¹,Zucenkiene Emile¹²,Griskevicius Laimonas¹²

Affiliation:

1. Faculty of Medicine Institute of Clinical Medicine Vilnius University Vilnius Lithuania

2. Hematology, Oncology and Transfusion Medicine Center Vilnius University Hospital Santaros Klinikos Vilnius Lithuania

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13527

Reference29 articles.

1. Research C for DE and FDA approves venetoclax in combination for AML in adults.FDA[Internet]. 2019 Dec 20.https://www.fda.gov/drugs/fda‐approves‐venetoclax‐combination‐aml‐adults. Accessed June 16 2020.

2. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

3. The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia

4. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

5. Venetoclax is safe and efficacious in relapsed/refractory AML

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

2. How I treat refractory and relapsed acute myeloid leukemia;Blood;2024-01-04

3. Novel therapies upon failure of HMA plus venetoclax;Hematology;2023-12-08

4. Venetoclax in Acute Myeloid Leukemia;Recent Patents on Anti-Cancer Drug Discovery;2023-02

5. Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents;Leukemia & Lymphoma;2022-09-15